Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Sponsor:
Pennsylvania State University
Sponsor Study ID:
BCC015
CTO #:
103253
NCT Number:
NCT04301843
Phase:
II
Protocol Type:
Treatment
Age Group:
Children
Disease Sites:
Soft Tissue
Study Objectives:
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
eConsent:
Not available
Study Documents:
Open Study Documents
(MUSC NetID required for document access)

For more information about this trial please contact the study team:

  • Medical University of South Carolina
    • Principal Investigator, Kraveka, Jacqueline, at kravekjm@musc.edu .
    • Study Coordinator, Pound, Ashton, at pound@musc.edu , or please call +1 843-792-6078.

Trial opened at the following institutions:

Medical University of South Carolina